Management is very aware and on specific timelines; with key milestones, imo. Who they are talking to, and the private equity with them lets me know this is not a chop-shop situation, these guys have positioned themselves well. Mass-liscensing play(s) in the works. The lifecycle of switching from oral, high concentration drugs which cause side-effects to lower dosage, more effective delivery mechanism solution is the mega-lotto play aspect here. Yet not as lotto as it may seem, imo.
$PULM
News 
Market Data 
Discover 
